PD-1/PD-L1调控及其在肿瘤靶向治疗的前景展望

倪杰明; 倪安平

doi:10.24920/21804

Your Location：

Home >

Browse articles >

PD-1/PD-L1调控及其在肿瘤靶向治疗的前景展望

Chinese Medical Sciences Journal 2018年33卷第3期页码：174-182

综述 | Updated：2024-04-10

- PD-1/PD-L1调控及其在肿瘤靶向治疗的前景展望
- Affiliations：
  
  1 Seven Year Program of China Medical University, Shenyang 110122, China
  2 Department of Clinical Laboratories, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
- Author bio：
  
  * Tel: 86-13311360359, E-mail: niap@pumch.cn
- Funds：
- DOI：10.24920/21804
  中图分类号：
- 网络出版日期：2018-09-20，
  
  纸质出版日期：2018-09-20
- Accepted：
Scan QR Code
倪杰明, 倪安平. PD-1/PD-L1调控及其在肿瘤靶向治疗的前景展望[J]. Chinese Medical Sciences Journal, 2018,33(3):174-182.

Ni Jieming, Ni Anping. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy[J]. Chinese medical sciences journal, 2018, 33(3): 174-182.
倪杰明, 倪安平. PD-1/PD-L1调控及其在肿瘤靶向治疗的前景展望[J]. Chinese Medical Sciences Journal, 2018,33(3):174-182. DOI： 10.24920/21804.

Ni Jieming, Ni Anping. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy[J]. Chinese medical sciences journal, 2018, 33(3): 174-182. DOI： 10.24920/21804.

摘要

PD-1/PD-L1 是重要的免疫检查点

PD-1/PD-L1功能障碍导致肿瘤转移和免疫逃逸。PI3K/Akt/mTOR、MAPK 信号网络诱导PD-1/PD-L1表达并促进肿瘤发展;转录因子 HIF、PTEN、p53、CDK5、BRD4、STAT 调节PD-1/PD-L1表达;PD-1/PD-L1水平也受表观修饰和翻译后修饰调节

以上调控机制均作为潜在的肿瘤治疗靶点。目前

PD-1/PD-L1单克隆抗体及小分子抑制剂联合治疗肿瘤在临床上取得了良好的效果。

Abstract

Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) is a significant immune checkpoint

and the dysfunction of this axis contributes to tumor metastasis and immune escape. PI3K/Akt/mTOR and MAPK signal network induces PD-1/PD-L1 expression and facilitates tumor progression. Transcriptional factors such as hypoxia induced factors

PTEN

p53

CDK5

BRD4

STAT modulate PD-1/PD-L1 expression. PD-1/PD-L1 level is also regulated

via

epigenetic and post-translational manner. The underlying mechanisms mentioned above may provide potential targets for tumor treatment. At present

the combination therapy of PD-1/PD-L1 monoclonal antibodies plus small molecular inhibitors has achieved good outcomes in tumor treatment.

关键词

Keywords

references

Sheppard KA , Fitz LJ , Lee JM , et al . PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3 signalosome and downstream signaling to PKC theta . FEBS Letters 2004 ; 574 ( 1-3 ): 37 - 41 . doi: 10.1016/j.febslet.2004.07.083 10.1016/j.febslet.2004.07.083 . DOI: 10.1016/j.febslet.2004.07.083 http://doi.org/10.1016/j.febslet.2004.07.083 http://doi.wiley.com/10.1016/j.febslet.2004.07.083 http://doi.wiley.com/10.1016/j.febslet.2004.07.083

Zhang B , Yu W , Feng X , et al . Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma . Med Oncol 2017 ; 34 ( 5 ): 1 - 9 . doi: 10.1007/s12032-017-0941-2 10.1007/s12032-017-0941-2 . DOI: 10.1007/s12032-016-0859-0 http://doi.org/10.1007/s12032-016-0859-0 http://link.springer.com/10.1007/s12032-016-0859-0 http://link.springer.com/10.1007/s12032-016-0859-0

Waldmann TA . The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy . Cancer Immunol Res 2015 ; 3 ( 3 ): 219 - 27 . doi: 10.1158/2326-6066.CIR-15-0009 10.1158/2326-6066.CIR-15-0009 . DOI: 10.1158/2326-6066.CIR-15-0009 http://doi.org/10.1158/2326-6066.CIR-15-0009 http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-15-0009 http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-15-0009

Smeltzer JP , Jones JM , Ziesmer SC , et al . Pattern of CD14 + follicular dendritic cells and PD1 + T cells independently predicts time to transformation in follicular lymphoma . Clin Cancer Res 2014 ; 20 ( 11 ): 2862 - 72 . doi: 10.1158/1078-0432.CCR-13-2367 10.1158/1078-0432.CCR-13-2367 . DOI: 10.1158/1078-0432.CCR-13-2367 http://doi.org/10.1158/1078-0432.CCR-13-2367 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-13-2367 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-13-2367

Kubo S , Yamada T , Osawa Y , et al . Cytosine-phosphate-guanosine-DNA induces CD274 expression in human B cells and suppresses T helper type 2 cytokine production in pollen antigen-stimulated CD4-positive cells . Clin Exp Immunol 2012 ; 169 ( 1 ): 1 - 9 . doi: 10.1111/j.1365-2249.2012.04585.x 10.1111/j.1365-2249.2012.04585.x . DOI: 10.1111/cei.2012.169.issue-1 http://doi.org/10.1111/cei.2012.169.issue-1 http://doi.wiley.com/10.1111/cei.2012.169.issue-1 http://doi.wiley.com/10.1111/cei.2012.169.issue-1

Bai J , Gao Z , Li X , et al . Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade . Oncotarget 2017 ; 8 ( 66 ): 110693 - 707 . doi: 10.18632/oncotarget.22690 10.18632/oncotarget.22690 . DOI: 10.18632/oncotarget.22690 http://doi.org/10.18632/oncotarget.22690 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746415/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746415/

Chen J , Jiang CC , Jin L , et al . Regulation of PD-L1: a novel role of pro-survival signalling in cancer . Ann Oncol 2016 ; 27 ( 3 ): 409 - 16 . doi: 10.1093/annonc/mdv615 10.1093/annonc/mdv615 . DOI: 10.1093/annonc/mdv615 http://doi.org/10.1093/annonc/mdv615 https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv615 https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv615

Dezutter-Dambuyant C , Durand I , Alberti L , et al . A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage . Oncoimmunology 2015 ; 5 ( 3 ): e1091146 . doi: 10.1080/2162402X.2015.1091146 10.1080/2162402X.2015.1091146 .

Yang L , Huang F , Mei J , et al . Posttranscriptional control of PD-L1 expression by 17β-estradiol via PI3K/Akt signaling pathway in ERα-positive cancer cell lines . Int J Gynecol Cancer 2017 ; 27 ( 2 ): 196 - 205 . doi: 10.1097/IGC.0000000000000875 10.1097/IGC.0000000000000875 . DOI: 10.1097/IGC.0000000000000875 http://doi.org/10.1097/IGC.0000000000000875 https://insights.ovid.com/crossref?an=00009577-201702000-00002 https://insights.ovid.com/crossref?an=00009577-201702000-00002

Ok CY , Young KH . Targeting the programmed death-1 pathway in lymphoid neoplasms . Cancer Treat Rev 2017 ; 54 ( 3 ): 99 - 109 . doi: 10.1016/j.ctrv.2017.01.009 10.1016/j.ctrv.2017.01.009 . DOI: 10.1016/j.ctrv.2017.01.009 http://doi.org/10.1016/j.ctrv.2017.01.009 https://linkinghub.elsevier.com/retrieve/pii/S030573721730018X https://linkinghub.elsevier.com/retrieve/pii/S030573721730018X

Sai J , Owens P , Novitskiy SV , et al . PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses . Clin Cancer Res 2017 ; 23 ( 13 ): 3371 - 84 . doi: 10.1158/1078-0432.CCR-16-2142 10.1158/1078-0432.CCR-16-2142 . DOI: 10.1158/1078-0432.CCR-16-2142 http://doi.org/10.1158/1078-0432.CCR-16-2142 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-2142 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-2142

Ma CX , Sanchez C , Gao F , et al . A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer . Clin Cancer Res 2016 ; 22 ( 11 ): 2650 - 8 . doi: 10.1158/1078-0432.CCR-15-2160 10.1158/1078-0432.CCR-15-2160 . DOI: 10.1158/1078-0432.CCR-15-2160 http://doi.org/10.1158/1078-0432.CCR-15-2160 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-2160 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-2160

Shayan G , Srivastava R , Li J , et al . Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer . Oncoimmunology 2017 ; 6 ( 1 ): e1261779 . doi: 10.1080/2162402X.2016.1261779 10.1080/2162402X.2016.1261779 . DOI: 10.1080/2162402X.2016.1261779 http://doi.org/10.1080/2162402X.2016.1261779 https://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1261779 https://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1261779

Busaidy NL , LoRusso P , Lawhorn K , et al . The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab . Oncologist 2015 ; 20 ( 7 ): 737 - 41 . doi: 10.1634/theoncologist.2015-0065 10.1634/theoncologist.2015-0065 . DOI: 10.1634/theoncologist.2015-0065 http://doi.org/10.1634/theoncologist.2015-0065 http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2015-0065 http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2015-0065

Cannon MJ , Goyne HE , Stone PJ , et al . Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4 + Th17 responses to ovarian tumor antigen . Cancer Immunol Immunother 2013 ; 62 ( 5 ): 839 - 49 . doi: 10.1007/s00262-013-1391-0 10.1007/s00262-013-1391-0 . DOI: 10.1007/s00262-013-1391-0 http://doi.org/10.1007/s00262-013-1391-0 http://link.springer.com/10.1007/s00262-013-1391-0 http://link.springer.com/10.1007/s00262-013-1391-0

Hugo W , Zaretsky JM , Sun L , et al . Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma . Cell 2016 ; 165 ( 1 ): 35 - 44 . doi: 10.1016/j.cell.2016.02.065 10.1016/j.cell.2016.02.065 . DOI: 10.1016/j.cell.2016.02.065 http://doi.org/10.1016/j.cell.2016.02.065 https://linkinghub.elsevier.com/retrieve/pii/S009286741630215X https://linkinghub.elsevier.com/retrieve/pii/S009286741630215X

Bally AP , Lu P , Tang Y , et al . NF-kappaB regulates PD-1 expression in macrophages . J Immunol 2015 ; 194 ( 9 ): 4545 - 54 . doi: 10.4049/jimmunol.1402550 10.4049/jimmunol.1402550 . DOI: 10.4049/jimmunol.1402550 http://doi.org/10.4049/jimmunol.1402550 http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1402550 http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1402550

Lin K , Cheng J , Yang T , et al . EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF- κB . Biochem Biophys Res Commun 2015 ; 463 ( 1-2 ): 95 - 101 . doi: 10.1016/j.bbrc.2015.05.030 10.1016/j.bbrc.2015.05.030 . DOI: 10.1016/j.bbrc.2015.05.030 http://doi.org/10.1016/j.bbrc.2015.05.030 https://linkinghub.elsevier.com/retrieve/pii/S0006291X15009444 https://linkinghub.elsevier.com/retrieve/pii/S0006291X15009444

Fraser SP , Hemsley F , Djamgoz MB . Caffeic acid phenethyl ester: inhibition of metastatic cell behaviours via voltage-gated sodium channel in human breast cancer in vitro . Int J Biochem Cell Biol 2016 ; 71 ( 2 ): 111 - 8 . doi: 10.1016/j.biocel.2015.12.012 10.1016/j.biocel.2015.12.012 . DOI: 10.1016/j.biocel.2015.12.012 http://doi.org/10.1016/j.biocel.2015.12.012 https://linkinghub.elsevier.com/retrieve/pii/S1357272515300856 https://linkinghub.elsevier.com/retrieve/pii/S1357272515300856

Tanaka T , Kutomi G , Kajiwara T , et al . Cancer-associated oxidoreductase ERO1-alpha promotes immune escape through up-regulation of PD-L1 in human breast cancer . Oncotarget 2017 ; 8 ( 15 ): 24706 - 18 . doi: 10.18632/oncotarget.14960 10.18632/oncotarget.14960 .

Naik R , Han S , Lee K . Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent . Arch Pharm Res 2015 ; 38 ( 9 ): 1563 - 74 . doi: 10.1007/s12272-015-0632-5 10.1007/s12272-015-0632-5 . DOI: 10.1007/s12272-015-0632-5 http://doi.org/10.1007/s12272-015-0632-5 http://link.springer.com/10.1007/s12272-015-0632-5 http://link.springer.com/10.1007/s12272-015-0632-5

Barsoum IB , Smallwood CA , Siemens DR , et al . A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells . Cancer Res 2014 ; 74 ( 3 ): 665 - 74 . doi: 10.1158/0008-5472.CAN-13-0992 10.1158/0008-5472.CAN-13-0992 . DOI: 10.1158/0008-5472.CAN-13-0992 http://doi.org/10.1158/0008-5472.CAN-13-0992 http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-13-0992 http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-13-0992

Chiker S , Pennaneach V , Loew D , et al . Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients . Cell Cycle 2015 ; 14 ( 19 ): 3066 - 78 . doi: 10.1080/15384101.2015.1078020 10.1080/15384101.2015.1078020 . DOI: 10.1080/15384101.2015.1078020 http://doi.org/10.1080/15384101.2015.1078020 https://www.tandfonline.com/doi/full/10.1080/15384101.2015.1078020 https://www.tandfonline.com/doi/full/10.1080/15384101.2015.1078020

Eggers JP , Grandgenett PM , Collisson EC , et al . Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras . Clin Cancer Res 2011 ; 17 ( 19 ): 6140 - 50 . doi: 10.1158/1078-0432.CCR-10-2288 10.1158/1078-0432.CCR-10-2288 . DOI: 10.1158/1078-0432.CCR-10-2288 http://doi.org/10.1158/1078-0432.CCR-10-2288 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-10-2288 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-10-2288

Patsoukis N , Li L , Sari D , et al . PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2 . Mol Cell Biol 2013 ; 33 ( 16 ): 3091 - 8 . doi: 10.1128/MCB.00319-13 10.1128/MCB.00319-13 . DOI: 10.1128/MCB.00319-13 http://doi.org/10.1128/MCB.00319-13 http://mcb.asm.org/lookup/doi/10.1128/MCB.00319-13 http://mcb.asm.org/lookup/doi/10.1128/MCB.00319-13

Cortez MA , Ivan C , Valdecanas D , et al . PDL1 regulation by p53 via miR-34 . J Natl Cancer Inst 2015 ; 108 ( 1 ). pii: djv303. doi: 10.1093/jnci/djv303 10.1093/jnci/djv303 . DOI: 10.1093/jnci/djv303 http://doi.org/10.1093/jnci/djv303 http://jnci.oxfordjournals.org/content/108/1/djv303.short http://jnci.oxfordjournals.org/content/108/1/djv303.short

Liu W , Ma Q , Wong K , et al . Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release . Cell 2013 ; 155 ( 7 ): 1581 - 95 . doi: 10.1016/j.cell.2013.10.056 10.1016/j.cell.2013.10.056 . DOI: 10.1016/j.cell.2013.10.056 http://doi.org/10.1016/j.cell.2013.10.056 http://linkinghub.elsevier.com/retrieve/pii/S0092867413014748 http://linkinghub.elsevier.com/retrieve/pii/S0092867413014748

Melaiu O , Mina M , Chierici M , et al . PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma . Clin Cancer Res 2017 ; 23 ( 15 ): 4462 - 72 . doi: 10.1158/1078-0432.CCR-16-2601 10.1158/1078-0432.CCR-16-2601 . DOI: 10.1158/1078-0432.CCR-16-2601 http://doi.org/10.1158/1078-0432.CCR-16-2601 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-2601 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-2601

Zhu H , Bengsch F , Svoronos N , et al . BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression . Cell Rep 2016 ; 16 ( 11 ): 2829 - 37 . doi: 10.1016/j.celrep.2016.08.032 10.1016/j.celrep.2016.08.032 . DOI: 10.1016/j.celrep.2016.08.032 http://doi.org/10.1016/j.celrep.2016.08.032 https://linkinghub.elsevier.com/retrieve/pii/S2211124716310968 https://linkinghub.elsevier.com/retrieve/pii/S2211124716310968

Lu C , Talukder A , Savage NM , et al . JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer . Oncoimmunology 2017 ; 6 ( 3 ): e1291106 . doi: 10.1080/2162402X.2017.1291106 10.1080/2162402X.2017.1291106 . DOI: 10.1080/2162402X.2017.1291106 http://doi.org/10.1080/2162402X.2017.1291106 https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1291106 https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1291106

Yao A , Liu F , Chen K , et al . Programmed death 1 deficiency induces the polarization of macrophages/microglia to the M1 phenotype after spinal cord injury in mice . Neurotherapeutics 2014 ; 11 ( 3 ): 636 - 50 . doi: 10.1007/s13311-013-0254-x 10.1007/s13311-013-0254-x . DOI: 10.1007/s13311-013-0254-x http://doi.org/10.1007/s13311-013-0254-x http://link.springer.com/10.1007/s13311-013-0254-x http://link.springer.com/10.1007/s13311-013-0254-x

Doi T , Ishikawa T , Okayama T , et al . The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines . Oncol Rep 2017 ; 37 ( 3 ): 1545 - 54 . doi: 10.3892/or.2017.5399 10.3892/or.2017.5399 . DOI: 10.3892/or.2017.5399 http://doi.org/10.3892/or.2017.5399 https://www.spandidos-publications.com/10.3892/or.2017.5399 https://www.spandidos-publications.com/10.3892/or.2017.5399

Borghaei H , Paz-Ares L , Horn L . Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer . N Engl J Med 2015 ; 373 ( 2 ): 1627 - 39 . doi: 10.1056/NEJMoa1507643 10.1056/NEJMoa1507643 . DOI: 10.1056/NEJMoa1507643 http://doi.org/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643

Robert C , Thomas L , Bondarenko I , et al . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma . N Engl J Med 2011 ; 364 ( 26 ): 2517 - 26 . doi: 10.1056/NEJMoa1104621 10.1056/NEJMoa1104621 . DOI: 10.1056/NEJMoa1104621 http://doi.org/10.1056/NEJMoa1104621 http://www.nejm.org/doi/abs/10.1056/NEJMoa1104621 http://www.nejm.org/doi/abs/10.1056/NEJMoa1104621

Gibney GT , Kudchadkar RR , DeConti RC , et al . Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma . Clin Cancer Res 2015 ; 21 ( 4 ): 712 - 20 . doi: 10.1158/1078-0432.CCR-14-2468 10.1158/1078-0432.CCR-14-2468 . DOI: 10.1158/1078-0432.CCR-14-2468 http://doi.org/10.1158/1078-0432.CCR-14-2468 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-2468 http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-2468

Zak KM , Grudnik P , Magiera K , et al . Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2 . Structure 2017 ; 25 ( 8 ): 1163 - 74 . doi: 10.1016/j.str.2017.06.011 10.1016/j.str.2017.06.011 . DOI: 10.1016/j.str.2017.06.011 http://doi.org/10.1016/j.str.2017.06.011 https://linkinghub.elsevier.com/retrieve/pii/S0969212617301910 https://linkinghub.elsevier.com/retrieve/pii/S0969212617301910

Taylor A , Harker JA , Chanthong K , et al . Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses . Immunity 2016 ; 44 ( 2 ): 274 - 86 . doi: 10.1016/j.immuni.2016.01.018 10.1016/j.immuni.2016.01.018 . DOI: 10.1016/j.immuni.2016.01.018 http://doi.org/10.1016/j.immuni.2016.01.018 https://linkinghub.elsevier.com/retrieve/pii/S107476131630005X https://linkinghub.elsevier.com/retrieve/pii/S107476131630005X

Mahoney KM , Freeman GJ , McDermott DF . The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma . Clin Ther 2015 ; 37 ( 4 ): 764 - 82 . doi: 10.1016/j.clinthera.2015.02.018 10.1016/j.clinthera.2015.02.018 . DOI: 10.1016/j.clinthera.2015.02.018 http://doi.org/10.1016/j.clinthera.2015.02.018 https://linkinghub.elsevier.com/retrieve/pii/S0149291815000880 https://linkinghub.elsevier.com/retrieve/pii/S0149291815000880

浏览量

2596

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

纳武单抗联合放疗治疗非小细胞肺癌引起严重皮肤反应1例报道